{"id":551269,"date":"2026-04-01T22:50:07","date_gmt":"2026-04-01T20:50:07","guid":{"rendered":"https:\/\/medizinonline.com\/de-nouvelles-references-therapeutiques-grace-a-shr-a-1811\/"},"modified":"2026-04-01T22:50:42","modified_gmt":"2026-04-01T20:50:42","slug":"de-nouvelles-references-therapeutiques-grace-a-shr-a-1811","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/de-nouvelles-references-therapeutiques-grace-a-shr-a-1811\/","title":{"rendered":"De nouvelles r\u00e9f\u00e9rences th\u00e9rapeutiques gr\u00e2ce \u00e0 SHR-A 1811"},"content":{"rendered":"\n

Le congr\u00e8s ESMO 2025 de cette ann\u00e9e a une nouvelle fois pr\u00e9sent\u00e9 un large \u00e9ventail de nouvelles donn\u00e9es sur le traitement du cancer du sein HER2-positif, dont l’analyse interm\u00e9diaire de l’\u00e9tude de phase 3 HORIZON-Breast01 pr\u00e9sent\u00e9e par Erwei Song (Sun-Yat-sen-University, Guangzhou). Cette \u00e9tude compare SHR-A 1811 au pyrotinib plus cap\u00e9citabine chez des patientes atteintes d’un cancer du sein m\u00e9tastatique HER2-positif. Elle fournit pour la premi\u00e8re fois des donn\u00e9es randomis\u00e9es sur ce nouveau conjugu\u00e9 anticorps-m\u00e9dicament cibl\u00e9 sur HER2. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Le congr\u00e8s ESMO 2025 de cette ann\u00e9e a une nouvelle fois pr\u00e9sent\u00e9 un large \u00e9ventail de nouvelles donn\u00e9es sur le traitement du cancer du sein HER2-positif, dont l’analyse interm\u00e9diaire de……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":551271,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancer du sein HER2+ m\u00e9tastas\u00e9 ","footnotes":""},"category":[11549,11527,11422,11389,11535],"tags":[89994,13591,89992,17491,90004,2343,89987,89989,89999,89996,89990,89349,89981,89986,90000,89985,89350,89403,90003],"powerkit_post_featured":[],"class_list":["post-551269","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-gynecologie","category-oncologie","category-rapports-de-congres","tag-analyse-interimaire-de-letude-de-phase-3-horizon-breast01","tag-cancer-du-sein","tag-cancer-du-sein-metastatique-her2-positif","tag-capecitabine","tag-congres-esmo-2025","tag-esmo","tag-etude-de-phase-1-horizon-x","tag-etude-pehdra","tag-etude-phoebe","tag-nouveaux-conjugues-anticorps-medicament-ciblant-her2","tag-profil-deffets-indesirables-shr-a-1811-vs-pyrotinib-capecitabine","tag-pyrotinib","tag-pyrotinib-plus-capecitabine","tag-sequencage-des-therapies-ciblees-her2","tag-shr-a-1811","tag-shr-a1811-trastuzumab-rezetecan","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-19 13:51:22","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":551270,"slug":"nuovi-standard-terapeutici-con-shr-a-1811","post_title":"Nuovi standard terapeutici con SHR-A 1811","href":"https:\/\/medizinonline.com\/it\/nuovi-standard-terapeutici-con-shr-a-1811\/"},"pt_PT":{"locale":"pt_PT","id":551276,"slug":"novos-padroes-terapeuticos-com-o-shr-a-1811","post_title":"Novos padr\u00f5es terap\u00eauticos com o SHR-A 1811","href":"https:\/\/medizinonline.com\/pt-pt\/novos-padroes-terapeuticos-com-o-shr-a-1811\/"},"es_ES":{"locale":"es_ES","id":551287,"slug":"nuevos-estandares-terapeuticos-con-shr-a-1811","post_title":"Nuevos est\u00e1ndares terap\u00e9uticos con SHR-A 1811","href":"https:\/\/medizinonline.com\/es\/nuevos-estandares-terapeuticos-con-shr-a-1811\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/551269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=551269"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/551269\/revisions"}],"predecessor-version":[{"id":551272,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/551269\/revisions\/551272"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/551271"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=551269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=551269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=551269"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=551269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}